Therapeutics

#Oncology #Therapeutics

Avacta appoints biotech executive and oncologist to bolster strategy

Avacta has appointed Dr Mark Goldberg as Non-executive Director to the Board with immediate effect. Dr Alastair Smith, Chief Executive Officer of Avacta, said Goldberg’s experience as a biotech executive and oncologist will greatly benefit the strategy and vision for the therapeutic business.  Dr Goldberg is a medical oncologist and haematologist on the faculty… Read More

#Business & Investment #News

#Pharma #Pharmaceuticals #Therapeutics

Digital brain biomarker start-up appoints Acacia founder to board 

Monument Therapeutics, a stratified medicine company, today announced Monument Therapeutics the appointment of Dr Julian Gilbert to its Board as a Non-Executive Director. Monument recently raised £2.625 million in seed funding and applies a novel drug development strategy, leveraging digital assessments of cognition to match patients with new pharmaceutical treatments.  The… Read More

#Business & Investment #News #Start-up Zone

#Biologics / Biotechnology #Covid-19 #HIV #In vivo #Therapeutics

Biotech start-up takes another stride toward flu cure 

Covimro, a British biotech start-up, has developed a food-grade compound which has demonstrated its efficacy against the flu virus in an animal model study carried out by A-IR Clinical Research and Pharmidex Pharmaceutical Services.  The in vivo testing analysed Covimro’s antiviral capability against an infection of Influenza A H3N2, a flu variant consistent with… Read More

#News #Start-up Zone

#Funding #Rare disease #Therapeutics

Angelini Pharma and Lumira Ventures launch the ALBF

Angelini Pharma and Lumira have launched the Angelini Lumira Biosciences Fund (ALBF), which has been established to invest in early-stage companies in Canada and U.S. markets that are developing pharmaceutical therapies for central nervous system disorders (CNS) and rare diseases. The ALBF will be managed by Lumira Ventures and Angelini… Read More

#News #Start-up Zone

#Biomanufacturing #Biosciences #Biotherapeutics #Drug development #Therapeutics

Partnership to develop and manufacture biosimilars

Abzena and BioXpress Therapeutics have partnered to support biosimilar development for third party customers, creating an integrated solution between two service providers with expertise in biosimilar development and GMP manufacture. The partnership will ensure biosimilar drug developers benefit from an integrated approach to biosimilars spanning the range from design consultancy,… Read More

#News

#Cancer research #Technology #Therapeutics #Tumour biology

First patient dosed in AVA6000 pro-Doxorubicin Phase I clinical trial

Avacta Group has dosed the first patient in its Phase I multicentre trial evaluating AVA6000, a novel pro-drug of Doxorubicin and the company’s first therapeutic based on its pre|CISION technology. The pre|CISION platform incorporates a substrate that is specifically cleaved by the protease fibroblast activation protein alpha (FAPa), which is… Read More

#News #Trending News

#Clinical trials #Covid-19 #Data #Funding #Therapeutics

Appili Therapeutics secures $3.5 million in funding

Appili Therapeutics has entered into a $3.5 million convertible security funding agreement with Lind Global Fund. The company intends to use the funding to advance the broader Appili pipeline, including ATI-2307, a novel clinical stage antifungal expected to enter Phase II study in 2022. It will also support the operations… Read More

#News

#Biologics #Biology #Data #Genetics / genomics #RNA #Therapeutics

Starting line: focus on Canadian start-ups

DDW Editor Lu Rahman selects three Canadian start-ups worth watching: AbCellera Biologics, BlueRock Therapeutics and Deep Genomics. AbCellera Biologics AbCellera Biologics was founded in 2012 as a spin out from the University of British Colombia. The company searches, decodes, and analyses natural immune systems to find antibodies that can be… Read More

#Business & Investment #Editor's Choice #Exclusive Content #News #Opinion #Start-up Zone

#Cell therapy #Clinical trials #Covid-19 #Drug development #Drug discovery #Drug targets #Stem cells #Therapeutics

Exploring iPSCs for individual and population health applications

Listen to this article on the DDW Podcast: Brad Hamilton, Founder and Chief Science Officer at GoodCell examines the potential of induced Pluripotent Stem Cells. Across the world, patients suffering from heart failure, donor organ rejection and many other life-altering illnesses are struggling to combat the symptoms of their conditions. What… Read More

#Editor's Choice #Exclusive Content #News

#Biotherapeutics #Clinical trial #mRNA #Therapeutics

Positive interim results from Phase I study for sickle cell disease treatment

Massachusetts-headquartered Fulcrum Therapeutics has announced positive interim results from the ongoing single and multiple-ascending dose (SAD and MAD) Phase I trial with FTX-6058 in healthy adult volunteers. FTX-6058 is an investigational, potent and selective small molecule inhibitor of EED designed to increase the expression of fetal hemoglobin (HbF) with the… Read More

#News #Trending News

#Assays #Biotherapeutics #C elegans #Drug development #Drug discovery #Therapeutics #Viosciences

Unlocking the microbiome as a target for drug discovery using C. elegans

David Weinkove, CEO Magnitude Biosciences, examines the untapped microbiome and its potential into helping unlock new therapies. Why the microbiome? The human microbiome is an important emerging field for drug discovery that harbours an array of life-changing medicines for patients. Whilst it is increasingly acknowledged that the human microbiome holds… Read More

#Cancer Research #Editor's Choice #Exclusive Content #News

#Biotherapeutics #Cancer immunotherapy #Cancer research #Chemotherapy #Oncology #Therapeutics

Study could combat aggressive chemotherapy resistant TNBC

A Mount Sinai study titled Simultaneous CK2/TNIK/DYRK1 inhibition by 108600 suppresses triple negative breast cancer stem cells and chemotherapy-resistant disease describes how a novel therapeutic (108600) combats aggressive chemotherapy-resistant triple-negative breast cancer (TBNC). 108600 targets and inhibits breast cancer stem cells, a subpopulation of cells found within patient triple negative… Read More

#Editor's Choice #News

#Drug development #Immunology / Virology & Vaccines #mRNA #Therapeutics

Sanofi to acquire Translate Bio

Sanofi has acquired Translate Bio as part of its endeavour to accelerate the application of mRNA to develop therapeutics and vaccines. Under the agreement, Sanofi will acquire all outstanding shares for a total equity value of approximately $3.2 billion (on a fully diluted basis). “Translate Bio adds an mRNA technology… Read More

#News #Trending News

#Clinical trials #Covid-19 #Moderna #mRNA #Therapeutics

Moderna doses first patient with its IL-2 mRNA therapeutic candidate

Moderna has dosed the first patients in the Phase I study of mRNA-6231, the company’s mRNA-encoded IL-2, modified for the expansion of regulatory T cells. mRNA-6231 is Moderna’s first autoimmune candidate to enter the clinic and its first subcutaneously administered therapeutic program. “The initiation of the Phase I study of… Read More

#News #Trending News

#Assays #Biotechnology #Life sciences #Therapeutics

PerkinElmer expands KRAS oncology drug discovery assays

PerkinElmer has released four new ready-to-use AlphaLISA KRAS kits, designed to help scientists better understand complex KRAS protein structures and mutations so they can more easily, quickly, and precisely identify potential new therapeutic candidates for a wide range of prevalent cancers. Researchers will now be able to choose between PerkinElmer’s… Read More

#News

#Cancer research #Checkpoint inhibitor therapies #Research #Therapeutics

Agreement signed to profile patients in immuno-oncology trial

Oncimmune Holdings has signed an autoantibody profiling contract with Dana-Farber Cancer Institute in Boston, Massachusetts. Dana-Farber, a clinical affiliate and research institute of Harvard Medical School, is a cancer research organisation and its cancer hospitals have more than 1,100 therapeutic and non-therapeutic clinical trials in progress. Under this agreement, Oncimmune… Read More

#News